Skip to main content
Erschienen in: Digestive Diseases and Sciences 6/2013

01.06.2013 | Original Article

Is the Proton Pump Inhibitor Test Helpful in Patients with Laryngeal Symptoms?

verfasst von: Jeong Hwan Kim, In-Kyung Sung, Sung Noh Hong, Sun-Young Lee, Hyung Seok Park, Chan Sup Shim

Erschienen in: Digestive Diseases and Sciences | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Background and Objectives

The association of gastroesophageal reflux disease (GERD) and laryngeal symptoms is not clear. We aimed to examine the symptomatic and endoscopic relations between GERD and laryngeal symptoms and also to evaluate the response to a 2-week proton pump inhibitor (PPI) trial.

Methods

Seventy-two patients experiencing persistent laryngeal symptoms ≥2/week were enrolled. The laryngeal symptoms using the 1-week laryngeal symptom score (LSS) and the typical reflux symptoms including heartburn and acid regurgitation were assessed. Transnasal-esophagogastroduodenoscopy (TN-EGD) and ambulatory 24-h esophageal pH monitoring were performed. The patients were classified into a GERD group and a non-GERD group. The GERD group was defined as the cases of the presence of typical reflux symptoms and/or reflux esophagitis and/or pathologic acid exposure. Patients were treated with 30 mg of lansoprazole bid for 14 days.

Results

Thirty-nine patients (54 %) were diagnosed with GERD on the basis of typical reflux symptoms, EGD, and/or pH testing. There was no significant association between the LSS and the presence of typical reflux symptoms. Also, the presence of laryngitis was not significantly related to reflux esophagitis. The 2-week PPI trial showed no significant difference in the improvement in laryngeal symptoms between the GERD and non-GERD groups.

Conclusions

There was no significant symptomatic and endoscopic association between GERD and laryngeal symptoms. Therefore, GERD does not appear to be the sole cause of these symptoms. Additionally, a 2-week PPI trial is not long enough to be a diagnostic tool in patients with laryngeal symptoms.
Literatur
1.
Zurück zum Zitat Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope. 1991;101:1–78.PubMedCrossRef Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope. 1991;101:1–78.PubMedCrossRef
2.
Zurück zum Zitat Graser AG. Gastroesophageal reflux and laryngeal symptoms. Aliment Pharmacol Ther. 1994;8:265–272. Graser AG. Gastroesophageal reflux and laryngeal symptoms. Aliment Pharmacol Ther. 1994;8:265–272.
3.
Zurück zum Zitat Sinn DH, Kim JH, Kim S, et al. Response rate and predictors of response in a short-term empirical trial of high-dose rabeprazole in patients with globus. Aliment Pharmacol Ther. 2008;27:1275–1281.PubMedCrossRef Sinn DH, Kim JH, Kim S, et al. Response rate and predictors of response in a short-term empirical trial of high-dose rabeprazole in patients with globus. Aliment Pharmacol Ther. 2008;27:1275–1281.PubMedCrossRef
4.
Zurück zum Zitat Qua CS, Wong CH, Gopala K, Goh KL. Gastro-oesophageal reflux disease in chronic laryngitis: prevalence and response to acid-suppressive therapy. Aliment Pharmacol Ther. 2007;25:287–295.PubMedCrossRef Qua CS, Wong CH, Gopala K, Goh KL. Gastro-oesophageal reflux disease in chronic laryngitis: prevalence and response to acid-suppressive therapy. Aliment Pharmacol Ther. 2007;25:287–295.PubMedCrossRef
5.
Zurück zum Zitat Wong CH, Chua CJ, Liam CK, Goh KL. Gastro-oesophageal reflux disease in ‘difficult-to-control’ asthma: prevalence and response to treatment with acid suppressive therapy. Aliment Pharmacol Ther. 2006;23:1321–1327.PubMedCrossRef Wong CH, Chua CJ, Liam CK, Goh KL. Gastro-oesophageal reflux disease in ‘difficult-to-control’ asthma: prevalence and response to treatment with acid suppressive therapy. Aliment Pharmacol Ther. 2006;23:1321–1327.PubMedCrossRef
6.
Zurück zum Zitat Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology. 1998;115:42–49.PubMedCrossRef Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology. 1998;115:42–49.PubMedCrossRef
7.
Zurück zum Zitat Sen P, Georgalas C, Bhattacharyya AK. A systematic review of the role of proton pump inhibitors for symptoms of laryngopharyngeal reflux. Clin Otolaryngol. 2006;31:20–24.PubMedCrossRef Sen P, Georgalas C, Bhattacharyya AK. A systematic review of the role of proton pump inhibitors for symptoms of laryngopharyngeal reflux. Clin Otolaryngol. 2006;31:20–24.PubMedCrossRef
8.
Zurück zum Zitat Karkos PD, Wilson JA. Empiric treatment of laryngopharyngeal reflux with proton pump inhibitors: a systematic review. Laryngoscope. 2006;116:144–148.PubMedCrossRef Karkos PD, Wilson JA. Empiric treatment of laryngopharyngeal reflux with proton pump inhibitors: a systematic review. Laryngoscope. 2006;116:144–148.PubMedCrossRef
9.
Zurück zum Zitat Kim JH, Sinn DH, Son HJ, Kim JJ, Rhee JC, Rhee PL. Comparison of one-week and two-week empirical trial with a high-dose rabeprazole in non-cardiac chest pain patients. J Gastroenterol Hepatol. 2009;24:1504–1509.PubMedCrossRef Kim JH, Sinn DH, Son HJ, Kim JJ, Rhee JC, Rhee PL. Comparison of one-week and two-week empirical trial with a high-dose rabeprazole in non-cardiac chest pain patients. J Gastroenterol Hepatol. 2009;24:1504–1509.PubMedCrossRef
10.
Zurück zum Zitat Seo TH, Kim JH, Lee JH, et al. Clinical distinct features of noncardiac chest pain in young patients. J Neurogastroenterol Motil. 2010;16:166–171.PubMedCrossRef Seo TH, Kim JH, Lee JH, et al. Clinical distinct features of noncardiac chest pain in young patients. J Neurogastroenterol Motil. 2010;16:166–171.PubMedCrossRef
11.
Zurück zum Zitat Williams RBH, Szczesniak MM, Maclean JC, Brake HM, Cole IE, Cook IJ. Predictors of outcome in an open label, therapeutic trial of high dose omeprazole in laryngitis. Am J Gastroenterol. 2004;85:778–788. Williams RBH, Szczesniak MM, Maclean JC, Brake HM, Cole IE, Cook IJ. Predictors of outcome in an open label, therapeutic trial of high dose omeprazole in laryngitis. Am J Gastroenterol. 2004;85:778–788.
12.
Zurück zum Zitat Wo JM, Grist WJ, Gussack G, Delgaudio JM, Waring JP. Empiric trial of high-dose omeprazole in patients with posterior laryngitis: a prospective study. Am J Gastroenterol. 1997;92:2160–2165.PubMed Wo JM, Grist WJ, Gussack G, Delgaudio JM, Waring JP. Empiric trial of high-dose omeprazole in patients with posterior laryngitis: a prospective study. Am J Gastroenterol. 1997;92:2160–2165.PubMed
13.
Zurück zum Zitat Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172–180.PubMedCrossRef Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172–180.PubMedCrossRef
14.
Zurück zum Zitat Jamieson JR, Stein HJ, DeMeester TR, et al. Ambulatory 24-h esophageal pH monitoring: normal values, optimal thresholds, specificity, sensitivity, and reproducibility. Am J Gastroenterol. 1992;87:1102–1111.PubMed Jamieson JR, Stein HJ, DeMeester TR, et al. Ambulatory 24-h esophageal pH monitoring: normal values, optimal thresholds, specificity, sensitivity, and reproducibility. Am J Gastroenterol. 1992;87:1102–1111.PubMed
15.
Zurück zum Zitat Preiss C, Charton JP, Schumacher B, Neuhaus H. A randomized trial of unsedated transnasal small-caliber esophagogastroduodenoscopy (EGD) versus peroral small-caliber EGD versus conventional EGD. Endoscopy 2003;35:641–646.PubMedCrossRef Preiss C, Charton JP, Schumacher B, Neuhaus H. A randomized trial of unsedated transnasal small-caliber esophagogastroduodenoscopy (EGD) versus peroral small-caliber EGD versus conventional EGD. Endoscopy 2003;35:641–646.PubMedCrossRef
16.
Zurück zum Zitat Andrus JG, Dolan RW, Anderson TD. Transnasal esophagoscopy: a high-yield diagnostic tool. Laryngoscope 2005;115:993–996.PubMedCrossRef Andrus JG, Dolan RW, Anderson TD. Transnasal esophagoscopy: a high-yield diagnostic tool. Laryngoscope 2005;115:993–996.PubMedCrossRef
17.
Zurück zum Zitat Stroppa I, Grasso E, Paoluzi OA, et al. Unsedated transnasal versus transoral sedated upper gastrointestinal endoscopy: a one-series prospective study on safety and patient acceptability. Dig Liver Dis. 2008;40:767–775.PubMedCrossRef Stroppa I, Grasso E, Paoluzi OA, et al. Unsedated transnasal versus transoral sedated upper gastrointestinal endoscopy: a one-series prospective study on safety and patient acceptability. Dig Liver Dis. 2008;40:767–775.PubMedCrossRef
18.
Zurück zum Zitat Choe WH, Kim JH, Ko SY, et al. Comparison of transnasal small-caliber vs. peroral conventional esophagogastroduodenoscopy for evaluating varices in unsedated cirrhotic patients. Endoscopy 2011;43:649–656.PubMedCrossRef Choe WH, Kim JH, Ko SY, et al. Comparison of transnasal small-caliber vs. peroral conventional esophagogastroduodenoscopy for evaluating varices in unsedated cirrhotic patients. Endoscopy 2011;43:649–656.PubMedCrossRef
19.
Zurück zum Zitat Wong WM. Use of proton pump inhibitor as a diagnostic test in NCCP. J Gastroenterol Hepatol. 2005;20:S14–S17.PubMedCrossRef Wong WM. Use of proton pump inhibitor as a diagnostic test in NCCP. J Gastroenterol Hepatol. 2005;20:S14–S17.PubMedCrossRef
20.
Zurück zum Zitat Bruley des Varannes S. The proton-pump inhibitor test: pros and cons. Eur J Gastroenterol Hepatol. 2004;16:847–852.PubMedCrossRef Bruley des Varannes S. The proton-pump inhibitor test: pros and cons. Eur J Gastroenterol Hepatol. 2004;16:847–852.PubMedCrossRef
21.
Zurück zum Zitat Vaezi MF. Therapy Insight: gastroesophageal reflux disease and laryngopharyngeal reflux. Nat Clin Pract Gastroenterol Hepatol. 2005;2:595–603.PubMedCrossRef Vaezi MF. Therapy Insight: gastroesophageal reflux disease and laryngopharyngeal reflux. Nat Clin Pract Gastroenterol Hepatol. 2005;2:595–603.PubMedCrossRef
22.
Metadaten
Titel
Is the Proton Pump Inhibitor Test Helpful in Patients with Laryngeal Symptoms?
verfasst von
Jeong Hwan Kim
In-Kyung Sung
Sung Noh Hong
Sun-Young Lee
Hyung Seok Park
Chan Sup Shim
Publikationsdatum
01.06.2013
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 6/2013
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2540-6

Weitere Artikel der Ausgabe 6/2013

Digestive Diseases and Sciences 6/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.